S&P Futures
4,272.00 -35.75 (-0.83%) Dow Futures
33,906.00 -212.00 (-0.62%) Nasdaq Futures
13,524.00 -134.25 (-0.98%) Russell 2000 Futures
2,004.60 -18.70 (-0.92%) Crude Oil
86.42 -0.11 (-0.13%) Gold
1,782.90 -6.80 (-0.38%)
Tempest Therapeutics, Inc. (TPST)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.4200 |
| Open | 2.6300 |
| Bid | 2.7900 x 800 |
| Ask | 2.9300 x 2200 |
| Day's Range | 2.6300 - 2.9000 |
| 52 Week Range | 2.0000 - 16.3900 |
| Volume | |
| Avg. Volume | 50,675 |
| Market Cap | 28.756M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.7630 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TPST
Related Research
- Tempest Therapeutics, Inc.Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.RatingFair ValueEconomic Moat6 days agoArgus Research
- GlobeNewswire
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2022 and provided a corporate update. “In the second quarter, we presented promising trial results from TPST-1120, our novel PPARα antagonist, at the ASCO Annual Meeting. This was the first present
- GlobeNewswire
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference
President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy TargetsSOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., will participate in a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the 2022 William Blair Biotech
- GlobeNewswire
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpectedRECIST responses observed with TPST-1120 combined with anti-PD1 therapy in patients who previously progressed on anti-PD1/PDL1 therapyPotential biomarker for patient responsiveness to TPST-1120 identified and will be further exploredTPST-1120 demonstrated the ability to reprogram the tumor microenvironment (TME) in a tumor type that is refractory to a
